reports
Genus: 2 directors
Two Directors at Genus bought/sold after exercising options 4,856 shares at between 1,733p and 1,854p. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...
- Martin Hall
Hardman & Co Healthcare Index: 2023 – Capital demands dent performance
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ETX E-THERAPEUTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
AVO ADVANCED ONCOTHERAPY
OXB OXFORD BIOMEDICA PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
SN/ IMMUPHARMA
IMM PROTEOME SCIENCES PLC
PRM GENUS PLC
GNS SURGICAL INNOVATIONS GROUP PLC
SUN ADVANCED MEDICAL SOLUTIONS GROUP PLC
AMS OXFORD METRICS
OMG ECO ANIMAL HEALTH GROUP
EAH SDI GROUP
SDI HVIVO
HVO INDIVIOR PLC
INDV VALIRX
VAL SHIELD THERAPEUTICS
STX SYNAIRGEN PLC
SNG IP GROUP
IPO SCANCELL HOLDINGS
SCLP SYNCONA
SYNC ERGOMED
ERGO SPIRE HEALTHCARE GROUP PLC
SPI REDX PHARMA
REDX ASSURA PLC
AGR GENEDRIVE
GDR SPIRE INC
SR CONVATEC GROUP PLC
CTEC DESTINY PHARMA
DEST RENEURON GROUP
RENE IXICO
IXI 10X GENOMICS INC CLASS A
TXG INDIVA LTD
NDVA IMMUNOCORE HOLDINGS ADS
IMCR 2SEVENTY BIO INC
TSVT OXFORD NANOPORE TECHNOLOGIES PLC
ONT SILENCE THERAPEUTICS PLC
SLN SAREUM HOLDINGS PLC
SAR BENEVOLENTAI
BAI 123FAHRSCHULE SE
123F 1895 BANCORP OF WISCONSIN INC
BCOW TISSUE REGENIX GROUP PLC
PLP.H 3D SIGNATURES INC
Z29 029 GROUP SE
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
- Edward Thomason
- Seb Jantet
LIBERUM: Genus* - Sticky Chinese Pork
For anyone watching the China pig price, today’s statement won’t be that much of a surprise, with prices staying persistently below expectations. This has hit Genus’ PIC China profits and, while the other parts of the business have helped to offset the impact, the net result is that Genus expects full year PBT to come in around 12% below our forecast. Conditions in China should eventually improve and with Genus shifting towards a royalty model in China, the risk of this happening again is reduci...
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
SRP SERCO GROUP PLC
HAS HAYS PLC
MGNS MORGAN SINDALL GROUP
GNS GENUS PLC
HWDN HOWDEN JOINERY GROUP PLC
TRCS TRACSIS
SRC SIGMAROC
AAL ANGLO AMERICAN
A2DVHX SUPERMARKET INCOME REIT PLC
HONY HONEYCOMB INVESTMENT TRUST
TRR TRIDENT ROYALTIES
HE1 HELIUM ONE GLOBAL
WISE WISE PLC
BYIT BYTES TECHNOLOGY GROUP PLC
AA4 AMEDEO AIR FOUR PLUS LTD
- Liberum Research Team
- Edward Thomason
- Seb Jantet
LIBERUM: Genus* - Strong H1 reduces full year risk
Genus delivered a strong set of interim results this morning, beating our forecasts. As ever with Genus there are a lot of moving parts, but a combination of Genus’ geographic diversification and continued shift towards royalties has helped iron out the ups and downs. We don’t expect to make any material changes to our forecasts on the back of today’s statement and the strong H1 together with an unexpected boost from resolving a patent dispute means that we think Genus no longer need to see volu...
An unfavourable environment weighs on GENUS, which sees a downgrade to...
The independent financial analyst theScreener just requalified the general evaluation of GENUS (GB), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date January 14, 2022, the closing pr...
Genus plc to Hold Capital Markets Event Today at 10:00 AM ET and Provi...
BASINGSTOKE, England & MADISON, Wis.--(BUSINESS WIRE)-- (LSE: GNS), a leading global animal genetics company, is hosting a Capital Markets Event (CME) today at 10 AM ET, 3pm UK time. The CME will cover key strategic progress and initiatives being implemented to further strengthen Genus’s leadership in the animal genetics market. The presentations given by members of Genus's executive management will be made available on the Company website after the event at: . As part of the CME, Genus’s Chief Scientific Officer Dr. Elena Rice will provide an update on Genus’s porcine reproductive and resp...
Genus plc Reports Interim First Half 2021 Fiscal Year Results
BASINGSTOKE, England & MADISON, Wis.--(BUSINESS WIRE)-- (LSE: GNS), a global biotechnology leader in animal genetics, today reported interim results for the six-months period ending December 31, 2020, as well as provided a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses. The full report has been made available on the section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights on a pre-recorded webcast, scheduled today, Thursday, February 25, 2021 at 7:01 AM GMT, 2:01 AM EST. A recordin...
Genus plc Provides Update on Financial Performance for First Half of F...
BASINGSTOKE, England & MADISON, Wis.--(BUSINESS WIRE)-- (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the six-months period ending December 31, 2020. The strong trading performance reported by the Company at its recent Annual General Meeting (AGM) on November 25, 2020 has continued through the first half of Genus’s financial year, and the adjusted profit before tax of the Group in actual currency is now expected to be within a range of £47.0m and £49.0m for the first half (six months to December 31, 2019: £...
Genus plc Provides Update on Fiscal 2021 Financial Performance
BASINGSTOKE, England & MADISON, Wis.--(BUSINESS WIRE)-- (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the period from July 1, 2020 through November 24, 2020, coinciding with its Annual General Meeting today at 11:00 am GMT. The positive financial and operational momentum we achieved last year across the Genus Group has continued into our 2021 financial year. In the first four months of fiscal 2021 through October 31, 2020, we achieved further strong growth in volumes, revenues and adjusted operating profits...
- Dave Nicoski
- Ross LaDuke
NEH NETEASE INC. SPONSORED ADR
CDR CEDAR REALTY TRUST INC
GNS GENUS PLC
KXS KINAXIS INC.
4686 JUSTSYSTEMS CORPORATION
600132 CHONGQING BREWERY CO.LTD CLASS A
4966 C. UYEMURA & CO. LTD.
NESTLEIND NESTLE INDIA LTD.
ATM A2 MILK COMPANY LTD.
6702 FUJITSU LIMITED
002511 C&S PAPER CO. LTD. CLASS A
002567 TANGRENSHEN GROUP (A)
002507 CHONGQING FULING ZHACAI GROUP CO. LTD. CLASS A
PDX PARADOX INTERACTIVE AB
603939 YIFENG PHARMACY CHAIN CO LTD CLASS A
2593 ITO EN LTD.
SE SEA ADS
603533 IREADER TECHNOLOGY (A)
3621M4107 GNS GROUP INC
GNSKF GARDEN SILK MILLS LTD.
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.